{"data":{"responsecode":"000","responsemsg":"","quote":{"hi":"9.530","rs_stock_flag":false,"fiscal_year_end":"2024年12月31日","hist_closedate":"2025年9月25日","replication_method":null,"amt_os":"788,408,880","primaryexch":"香港交易所","ric":"1167.HK","product_subtype":null,"db_updatetime":"2025年9月28日08:06","mkt_cap_u":"B","am_u":"M","ew_sub_right":"","secondary_listing":false,"ew_amt_os_cur":null,"ccy":"HKD","management_fee":"","ew_underlying_code":null,"trdstatus":"N","nav":"","original_offer_price":"","issue":"","asset_class":null,"eps":0.0,"inline_upper_strike_price":"","sedol":"BMQC6Q1","am":"56.51","iv":"","ew_strike":"","as":"9.260","geographic_focus":null,"incorpin":"開曼群島","etp_baseCur":null,"ew_amt_os":"","bd":"9.240","registrar":"香港中央證券登記有限公司","depositary":null,"exotic_type":null,"callput_indicator":null,"primary_market":null,"underlying_index":null,"lot":"300","update_time":"2025-09-28 00:06:03.0","lo52":"1.200","shares_issued_date":"2025年9月25日","premium":"","strike_price_ccy":null,"yield":"","vo_u":"M","base_currency":null,"coupon":"","expiry_date":"","chairman":"王印祥","underlying_ric":"1167.HK","hi52":"11.800","issuer_name":"加科思藥業集團有限公司 - B","h_share_flag":false,"ew_sub_per_from":"","div_yield":"","interest_payment_date":"-","updatetime":"2025年9月26日16:08","aum_date":"","lo":"8.830","mkt_cap":"7.28","f_aum_hkd":null,"ew_sub_per_to":"","ls":"9.240","nav_date":"","csic_classification":null,"floating_flag":false,"issued_shares_note":null,"nom_ccy":null,"eff_gear":"","board_lot_nominal":null,"hsic_ind_classification":"醫療保健業 - 藥品及生物科技","ew_desc":null,"inception_date":"","nc":"+0.090","aum":"","issued_shares_class_B":null,"vo":"6.07","secondary_listing_flag":false,"listing_date":"2020年12月21日","issued_shares_class_A":null,"as_at_label":"截至","ew_amt_os_dat":"","nm":"加科思藥業集團有限公司 - B","nm_s":"加科思－Ｂ","sym":"1167","inline_lower_strike_price":"","listing_category":"主要上市","ew_strike_cur":null,"exotic_warrant_indicator":null,"investment_focus":null,"call_price":"","tck":"0.010","strike_price":"","summary":"加科思藥業集團有限公司是一家主要從事臨床階段新藥研發的投資控股公司。該公司主要負責創新腫瘤療法的自主發現和開發。該公司主要藥物開發項目包括JAB-21822及JAB-3312臨床階段的變構SHP2抑制劑。該公司主要在中國市場開展業務。","op":"9.150","aum_u":"","nav_ccy":null,"class_B_description":null,"os":"","wnt_gear":"","transfer_of_listing_date":"","hsic_sub_sector_classification":"生物技術","amt_ccy":null,"class_A_description":null,"domicile_country":null,"entitlement_ratio":"","product_type":"EQTY","office_address":"香港灣仔<br/>皇后大道東248號<br/>大新金融中心<br/>40層","pc":"+0.98","days_to_expiry":null,"underlying_code":null,"pe":"","eps_ccy":"RMB","hdr":false,"launch_date":"","hc":"9.150","isin":"KYG4987A1094","moneyness":""}},"qid":"1759074211969"}
